Hall Capital Management Co. Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.1% in the first quarter, according to the company in its most recent filing with the SEC. The firm owned 31,583 shares of the company’s stock after acquiring an additional 343 shares during the quarter. Johnson & Johnson comprises about 2.9% of Hall Capital Management Co. Inc.’s portfolio, making the stock its 7th largest position. Hall Capital Management Co. Inc.’s holdings in Johnson & Johnson were worth $4,895,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Johnson & Johnson by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after purchasing an additional 2,815,655 shares in the last quarter. State Street Corp increased its stake in shares of Johnson & Johnson by 0.6% in the 3rd quarter. State Street Corp now owns 141,886,311 shares of the company’s stock valued at $23,178,548,000 after purchasing an additional 803,013 shares in the last quarter. Moneta Group Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Johnson & Johnson by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 47,958,583 shares of the company’s stock valued at $8,456,643,000 after purchasing an additional 294,671 shares in the last quarter. Finally, Morgan Stanley increased its stake in Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares in the last quarter. Hedge funds and other institutional investors own 67.57% of the company’s stock.
Johnson & Johnson Trading Down 1.4 %
Shares of Johnson & Johnson stock opened at $163.26 on Tuesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04. The company has a market capitalization of $424.27 billion, a P/E ratio of 34.15, a P/E/G ratio of 2.83 and a beta of 0.55. The business has a 50 day moving average price of $160.78 and a 200 day moving average price of $162.82.
Johnson & Johnson Increases Dividend
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd were issued a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.92%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date was Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is presently 99.58%.
Wall Street Analysts Forecast Growth
JNJ has been the subject of several research reports. Citigroup initiated coverage on Johnson & Johnson in a research note on Tuesday, May 30th. They set a “buy” rating and a $185.00 price objective for the company. UBS Group initiated coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price objective for the company. Atlantic Securities cut their price objective on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research note on Wednesday, April 19th. Credit Suisse Group boosted their price objective on Johnson & Johnson from $168.00 to $170.00 in a research note on Friday, May 5th. Finally, Raymond James lowered their target price on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a report on Wednesday, April 19th. Seven equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.57.
Insider Transactions at Johnson & Johnson
In other news, EVP Kathryn E. Wengel sold 12,465 shares of the company’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.20% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- Tesla Production Cranks Into High Gear, Shares Follow
- Ford Soars 30% YTD After Breaking Out: What’s Next?
- Acuity Brands Lights Up Opportunity In The Industrial Sector
- Overstock Looks Beyond Overbought After Bed Bath Re-Brand
- Tecnoglass Shines Bright As Analysts Bullish On Growth Potential
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
